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AA arachidonic acid 
AC    adenylyl cyclase 
Bad Bcl associated death protein 
Bax Bcl-2-associated X protein 
Bcl-2 B-cell lymphoma 2 
Bcl-XL Bcl-Xlong protein 
bFGF   basic fibroblast growth factor 
BrdU 5-bromo-2'-deoxyuridine 
cAMP   cyclic adenosine monophosphate 
CD cluster of differentiation 
CDK    cyclin-dependent kinase 
COX   cyclooxygenase 
cPGES   cytosolic prostaglandin E synthase 
cPLA2 cytosolic phospholipase A2 
CREB cAMP-response element binding protein 
E2 estradiol 
EC endometrial cancer 
ECL2 the second extracellular loop 
EEC     endometrial epithelial cell 
EGFR   epidermal growth factor receptor 
EGR-1                   early growth response protein 1 
EP   prostaglandin E receptor 
EPAC exchange protein activated by cAMP 
ER estrogen receptor 
ERK extracellular signal-regulated kinase 
ESC    endometrial stromal cells 
FAK focal adhesion kinase 
GPCR G-protein coupled receptor 
HGF hepatocyte growth factor 
HIF-1α                   hypoxia-inducible factor-1α 
ICL2   the second intercellular loop 
IL-8                       interleukin-8 
iPLA2 Ca2+-independent phospholipase A2 
IRS immunoreactive score  
LPS lipopolysaccharide 
Mφ macrophages 
MMP   matrix metalloproteinase 
mPGES membrane-bound PGES 
MRP4 resistance protein 4 
mTOR mammalian target of rapamycin 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MVD   microvessel density 
NF-κB                    nuclear factor kappa-light-chain-enhancer of activated B cells 
NK natural killer 






PGES prostaglandin E synthase 
PGG2 prostaglandin G2 
PGH2   prostaglandin H2 
PGT prostaglandin transporter 
PI3K phosphoinositide-3 kinase 
PKC protein kinase C 
PLA2 phospholipase A2 
PLC phospholipase C 
PRB progesterone receptor B 
Ras rat sarcoma 
RERG Ras-like, estrogen-regulated, growth inhibitor  
sPLA2 secretory phospholipase A2 
SUMO-1                enhancing small ubiquitin-like modifier 1 
TMVII the seventh transmembrane domain 
TXA2   thromboxane A2 
VEGF vascular endothelial growth factor 
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4.1 Human endometrium and its common diseases 
The primary function of human endometrium is to orchestrate the success of implantation and subsequent fetal 
growth and maturation [1,2]. Human endometrium is composed of the superficial “functionalis” layer and the 
deeper “basalis” layer according to distinct responses to estrogen and progesterone (P4) and different functions 
[2,3]. The former one consists of luminal epithelium, majority of glands lined by epithelium, and stroma [2]. The 
latter one, containing fewer glands and compact stroma, acts as the seat of the regenerative functionalis layer and 
the main component of the postmenopausal endometrium [2,3]. Endometrial stromal cells within proper 
extracellular matrices regulate epithelial cells growth and differentiation [4]. In addition, cycle-dependent 
immune cells exist in both layers [5]. Human endometrium undergoes a cyclic morphological change in response 
to fluctuating sex hormones and inflammatory mediators before menopause [1,2]. It is classified into 
proliferative, secretory and menstrual phases (Fig. 1). During the proliferative phase, all the tissue components 
including glandular, stromal and vascular endothelial cells increase and peak between cycle days 8 and 10, 
mainly under the control of estradiol (E2). Following ovulation, under the influence of P4, the endometrium 
undergoes secretory differentiation, which is characterized by active apocrine secretion of glycoproteins, edema, 
coiling of spiral arterioles, and predecidualization of the stroma. In the absence of conception, withdrawal of 
estrogen and P4 leads to the shedding of the endometrium and this process is limited to the functionalis layer [3]. 
Endometriosis and endometrial cancer (EC) are common endometrial diseases [2]. Endometriosis is 
characterized by endometrial-like tissue appearing outside the uterine cavity [2]. Major phenotypes include 
ovarian endometrioma, superficial peritoneal endometriosis, and deep infiltrating endometriosis [6,7]. Pelvic 
pain, such as dysmenorrhea, dyspareunia, non-period chronic pelvic pain and dyschezia, and infertility are 
among the most common symptoms. In less frequent but more severe cases, endometriosis implants may 
infiltrate the pelvic organs and cause intestinal perforation and obstruction [8]. Although being a benign disorder, 
endometriosis greatly affects the patients’ life quality. Although several theories have been proposed, the 
underlying pathogenesis remains unclear. Either drug treatments or surgeries are only effective for temporarily 
alleviating symptoms [7]. EC is a tumor originated from the endometrium and endometrioid adenocarcinoma is 
the most common histological subtype. Although it is often diagnosed at an early stage with good prognosis, its 
survival has actually not been improved since 1990 in European countries [9]. Furthermore, it receives more 
attention because of its growing morbidity. EC has become the most frequent gynecological carcinoma in more 
developed regions in 2012, where the incidence was estimated to be 14.7 per 100,000 [10,11]. For a long period, 
EC has been classified into two pathogenic types (type I and II) based on endocrine features to guide the 
treatment or predict the outcome [12]. However, this dualistic classification fails to explain the heterogeneity 
from biological and molecular features to prognosis [13]. Studies on molecular features of EC are emerging to 





Figure 1. The levels of ovarian hormones and prostaglandin E2 (PGE2) in the menstrual cycle. This 
illustration depicts the change of endometrium under the control of estrogen and progesterone and the 
simultaneous fluctuation of PGE2.  
4.2 Biosynthesis of prostaglandin E2 
Prostaglandin (PG) E2, a member of the prostanoid family, is a lipid mediator formed ubiquitously in human 
bodies and plays an extensive role in immune response [15], inflammation [16], pain perception [17], fever [18], 
oncogenesis [19], female fertilization and parturition [20]. Non-steroidal anti-inflammatory drugs (NSAIDs) for 
the treatment of pain and inflammation are believed to function to a large extent via targeting the PGE2 signal 
[21-23]. PGE2 exerts its biological actions via binding to its seven-transmembrane, G-protein coupled receptors 
(GPCRs), termed prostaglandin E receptor (EP) 1, EP2, EP3 and EP4 [11,24]. It is well described to be 
associated with both endometrial functions [25] and disorders [26]. 
The biosynthesis of PGE2 is a three-step process and three types of enzymes are included (Fig. 2). 
Firstly, arachidonic acid (AA) is released from plasma membrane phospholipids, after hydrolysis of sn-2 bond 
by phospholipase A2 (PLA2). Although secretory PLA2 (sPLA2), cytosolic PLA2 (cPLA2) and Ca(2+)-
independent PLA2 (iPLA2) are all involved in this reaction, only cPLA2alpha shows a preference for AA in the 
sn-2 position, which makes it a potential target for inhibiting the production of AA [27].  
The released AA is then converted successively to prostaglandin G2 (PGG2) and prostaglandin H2 
(PGH2), the two unstable intermediates by the action of cyclooxygenase (COX) [28]. Three isoforms of COX 
enzymes have been described: COX-1, COX-2, and COX-3. Because COX-1 is constitutively expressed at low 
levels in most tissues and at high levels in stomach and platelets, COX-1 was initially considered to be only 




research continues, the findings that COX-1 is also upregulated in inflammation [29,30], pain perception [31] 
and tumors [32,33] and highly selective COX-1 inhibitors can inhibit PGE2 production, nuclear factor kappa-
light-chain-enhancer of activated B cells (NF- κB) activation and inflammatory cell influx, suggest a role of 
COX-1 in pathological phenomena [34,35]. Since COX-2 was discovered in 1991, a lot of research has been 
performed to compare these two isoenzymes in structure and function. Although the genes for COX enzymes are 
mapped to different chromosomes: the gene for COX-1 is on chromosome 9q32-q33.3, the gene for COX-2 is on 
chromosome 1q25.2-q25.3, the amino acid sequences of both COX proteins are highly conserved [36]. The 
differences in regulatory regions, as well as coding sequences of the genes, contribute to distinct expressions and 
functions [37,38]. COX-2 has been demonstrated to be an immediate-early gene and quickly induced by stimuli. 
In the inflammatory context, inducible PGE2 production, anorexia, hyperalgesia, and fever are mainly dependent 
on COX-2, while COX-1 plays a role in avoiding hypothermia [38-41]. Both COX-1 and COX-2 deficient mice 
show reduced tumorigenesis [42]. In a solid tumor, COX-2 has been found to prompt angiogenesis [43] and 
proliferation [44]. Consistently, exposure to COX-2 inhibitor induces apoptosis [45]. A recent study has revealed 
that aspirin’s chemoprotective activity is due to inhibition of COX-1-mediated platelet activation and consequent 
blockade of the interaction between tumor cells and their microenvironment [46].  
COX-3 is generated by alternative splicing from COX-1 and highly expressed in cerebral cortex and 
heart. The COX activity of COX-3 determined by PGE2 production shows only about 20% of that of COX-1 
[47]. The precise role, which COX-3 plays in the physiological and pathological process, remains to be 
elucidated. 
Finally, the unstable precursor — PGH2, is catalyzed to different prostanoids, including PGE2, PGF2α, 
PGD2, PGI2, and thromboxane A2 (TXA2) by their respective terminal PG synthases, PGE synthase (PGES), 
PGI synthase, PGD synthase, PGF synthase, and thromboxane synthase [24]. Membrane-bound PGES-1 
(mPGES-1), mPGES-2, and cytosolic PGES (cPGES) are the three distinct forms of PGES [48].  
mPGES-1 is mainly expressed in the urogenital system at an intermediate level and colocalized with 
COX enzymes on nuclear membranes. mPGES-1 is preferentially coupled with COX-2 to produce delayed and 
immediate induction of PGE2 [49]. In addition, a selective COX-2 inhibitor is showed to attenuate the induction 
of mPGES-1, suggesting COX-2 is essential to mPGES-1 and inhibition of either mPGES-1 or COX-2 affects 
the PGE2 biosynthesis [50]. mPGES-1 also shows the capability to couple with COX-1 by supplied with high 
concentration exogenous or endogenous AA [49]. It can be markedly induced by proinflammatory stimuli, tissue 
damage and tumor, which makes it a potential therapeutic target for several diseases [51].  
mPGES-2 is located on Golgi membrane and constitutively expressed in heart, brain, lung, liver, and 
colon. Only the expression in liver and colon can be upregulated by lipopolysaccharides (LPS) stimulation. 
Consistent with that, its expression is elevated in colorectal cancer while keeping unchanged in inflammatory 
diseases and tissue damage. It can prompt immediate and delayed PEG2 biosynthesis via both COX enzymes 
with a slight COX-2-preference, suggesting it may be involved in organism homeostasis as well as diseases [51]. 
However, a recent report demonstrating PGE2 expression in mPGES-2 deficient mice was equal to that in 
healthy mice implies the little importance of mPGES-2 as a terminal synthase [52]. The possibility remains that 




RNA blot analysis identifies cPGES expression to be ubiquitous and constitutive with the exception that 
it could be induced remarkably following LPS treatment in brain tissue. Confocal microscopic analysis reveals it 
is located in the cytoplasm of the cells. cPGES pairs functionally with constitutive COX-1 to produce PGE2 
from exogenous and endogenous AA [53]. Moreover, in cells lack of mPGES-1, cPGES is able to pair with 
COX-2 to produce a modest amount of PGE2 [54]. Thus, cPGES is essential to maintenance of tissue 
homeostasis. 
Following synthesis, PGE2 is transported across the plasma membrane by multidrug resistance protein 
4 (MRP4) [55] and activates its receptors (Fig. 2). Alternatively, newly synthesized extracellular PGE2 is 
imported back into cells via the prostaglandin transporter (PGT) to suppress the signal pathway by preventing 
PGE2 from attaching to EPs (Fig. 2) [56,57].   
4.3 Structures and pathways of EPs 
Although recognizing PGE2 as a ligand, the homology among these receptors is limited. Both EP1 and EP2 
share more identities with other prostanoid receptors than with other EPs [58]. Among several conserved regions 
of EPs, the most highly conserved regions are located in the second extracellular loop (ECL2) and the seventh 
transmembrane domain (TMVII) [58]. All the EPs had been cloned by 1994. Afterward, the amino acid 
sequences have been compared to elucidate the prostaglandin receptor-specific events and understand the 
structure-function relationships of GPCRs. The aromatic amino acids in the second intercellular loop (ICL2) of 
EP2 is identified to mediate the Gs protein coupling, which offers an insight into the role of ICL2 of other 
GPCRs in coupling with G protein [59,60].  Other studies focusing on highly conserved residues among EPs of 
many species have identified that arginine residue in TMVII is essential to selective G protein coupling [61], 
while serine residue in TMVI and threonine residue in ECL2 are essential to ligand binding [62,63]. 
EP1 is mainly coupled to Gq/G11 and induces the Ca(2+) mobilization and activates protein kinase C 
(PKC) by phospholipase C (PLC) -dependent pathway (Fig. 2) [64,65]. Its downstream effectors include c-Src, 
focal adhesion kinase (FAK), NF-κB [66-68]. Recent studies show the EP1-mediated PKC is also responsible for 
cyclic adenosine monophosphate (cAMP) formation and the following cAMP/PKA/cAMP-response element 
binding protein (CREB) pathway, which might reveal the interaction among EPs in this pathway [69,70]. 
Additionally, that EP1 is able to upregulate the expression of hypoxia-inducible factor-1α (HIF-1α) via 
activation of phosphoinositide-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling by 
coupling to Gi/Go has also been reported [65]. 
EP2 and EP4 have long been known to activate cAMP/PKA/CREB signaling pathway via Gs (Fig. 2). 
Besides, both receptors are able to induce the translocation of β-catenin, which is involved in promoting gene 
transcription [71]. Following activation of cAMP, either of them also induces a PKA-independent exchange 
protein activated by cAMP (EPAC) pathway [72-74]. However, consistent with different molecular structures, 
ligand infinities, and distributions, there are several fundamental differences in signaling transduction between 
EP2 and EP4. The most important one is that EP4, rather than EP2, couples to Gi/Go and is responsible for the 
subsequent PI3K pathway, including phosphorylation of the extracellular signal-regulated kinase (ERK)1/2 and 
induction of early growth response protein 1 (EGR-1) [75,76]. Furthermore, the translocation of β-catenin and 




activation is PI3K-dependent to a large extent, while the one mediated by EP2 is PKA-dependent [71,77]. In 
addition, the findings that PI3K inhibits the activity of PKA underlie the connection between these two major 
pathways [77]. These similarities and differences in signaling and the close interaction among them indicate a 
fine and complex regulation of EP2 and EP4 signaling transduction.  
EP3 stimulation mainly induces inhibition of adenylyl cyclase (AC) activity and enhances the Ca(2+) 
entry and mobilization via Gi-coupling (Fig. 2) [24,78]. However, among four EPs, EP3 is the most unique due 
to its diverse C-terminal tails by alternative splicing [11]. For example, human EP3 gene, containing ten exons 
and nine introns, generates nine distinct mRNAs and encodes at least eight isoforms [11,79]. Consistent with its 
multiple splicing variants, EP3 has been reported to activate AC and Rho protein via Gs and G12/G13 [80]. 
Therefore, its downstream targets include the majority of pathways of the other EPs, such as PKA/β-catenin 
[81,82], PI3K/AKT signaling [83,84]. In addition, one bovine isoform of EP3 is indicated to induce 
phosphatidylinositol turnover and intercellular Ca(2+) increase by coupling to Gq/G11 [85].  
 
Figure 2. PGE2 biosynthesis and signaling pathways. AA is released and ultimately catalyzed into PGE2. 
Following transported across the plasma membrane, PGE2 binds to its receptors, EP1-4 and in turn, activates 
different associated G proteins and downstream signaling pathways. 
4.4 PGE2 pathway in healthy and diseased endometrium 
PGE2 is the predominant product by endometrium instead of by myometrium, implying its major role in 
endometrium [86]. So far, PGE2 has been confirmed to play an essential role in implantation, consistent with the 
fact that its secretion increases during the window of implantation and last through the menstrual period (Fig. 1) 
[87-89]. Inhibition of COX greatly decreases the mouse embryo adhesion to human endometrial epithelial cells 




the embryo adhesion by 20% [88]. Besides, PGE2 is also indispensable to induce the vascular permeability and 
angiogenesis and transform stromal cells into decidual cells during implantation [90]. Therefore, the 
concentration of PGE2 in endometrial fluid is considered as a biomarker of endometrial receptivity [88]. In 
addition, PGE2 is proposed to participate in the endometrial repair process in menstruation by upregulating an 
angiogenic factor, interleukin-8 (IL-8) [91]. 
COX-2 and mPGES-1 expression are higher in endometriotic lesions than in normal eutopic 
endometrium [92,93]. Concordantly, PGE2, secreted predominantly by endometrial stromal cells (ESCs) and 
macrophages (Mφ), also displays an increase in peritoneal fluid and menstrual fluid of women with 
endometriosis [94,95]. EP4 gene expresses the highest in ESCs among four EPs and together with EP3 mRNA, 
is reported to be significantly up-regulated in endometriotic tissue [96,97]. The over-expression of COX-2 and 
the resulting high production of PGE2 are closely linked to pain, infertility and a high risk of recurrence [98-100]. 
NSAIDs, which inhibit the COXs activity, are the most commonly used medication for relieving pain. A 
selective COX-2 inhibitor is effective to prevent the ectopic implants in rats [101,102].  
The correlation between COX, PGE2, and EC has also been well identified. The expression of COX-2 
and PTGES2, which is essential to PGE2 synthesis, is markedly elevated in EC as compared to the normal 
endometrium and this increased expression is associated with advanced stage, poor grade and deep myometrial 
invasion [103,104]. A study reported that COX-2 also predicted poor prognosis in EC [105]. COX-1 expression 
is more abundant in well-differentiated EC and therefore thought to be involved in the early stage of the disease 
[106]. Consistently, PGE2 secretion and EP2/EP4 mRNA are higher in tumor tissue [89,107]. And more 
remarkable, the synthesis of PGE2 is localized in neoplastic epithelial cells rather than in stromal cells, the usual 
localization in normal tissue. The transition from stroma to epithelium ensures the production of PGE2 is not 
affected by the loss of endometrial stroma during the evolution of EC, implying that PGE2 regulates the function 
of neoplastic cells in an autocrine/paracrine manner via EP2/EP4 [107,108]. Moreover, the high-frequency use of 
aspirin and the regular use of selective COX-2 inhibitors have been suggested to reduce the risk of EC in certain 
groups of women [109,110].  
Feedback regulation of COX-2 by PGE2 has been reported in both cultured cells and animal models 
[111]. In several malignant endometrial epithelial cell lines, PGE2 is observed to be the positive regulator of 
COX-2 by activating COX-2 transcription and stabilizing COX-2 mRNA, which indicates PGE2 is able to 
accumulate continuously in the local tumor in an autocrine/paracrine manner [112-114]. Regarding 
endometriosis, one study hypothesizes a negative COX-2 feedback by PGE2, although it presents no convincing 
evidence [115]. 
4.5 The interaction between PGE2 and hormones in the endometrium 
The endometrium is one of the tissues most affected by the sex steroid. Many reports suggest that sex steroid can 
also adjust and control PGE2 pathway in the endometrium, although the exact mechanisms by which estrogen 
and P4 function independently and/or together to regulate PGE2 pathway are not clear. E2 can increase the 
PGE2 secretion and P4 acts the opposite in vitro, although exposure to either of them upregulates COX-2 
expression [116,117]. Further, EPs are demonstrated to be under the control of sex hormones. In ovariectomized 




Treatment with P4 alone has no effect on any of the receptors. The differential responses to estrogen might be 
due to the existence of two different estrogen receptors [118]. The steroidal regulation of PGE2 signaling is also 
supported by the temporal pattern in human endometrium across the menstrual cycle. COX-1 expression levels 
are generally higher in secretory phase and probably the highest in mid-secretory phase, while COX-2 
expression increases significantly in late secretory following P4 withdrawal and maintains a high level 
throughout proliferative phase [119-121]. PGT sharply increases during the secretory phase, while MRP4 
expression has no significant difference across the whole menstrual cycle [97]. mPGES-1, mPGES-2, and 
cPGES express quite different and peak at late secretory, mid-secretory, and menstrual phase, respectively [122]. 
Concerning with EPs, although some expressions also show a temporal-specific manner based on RNA levels, 
the patterns vary wildly between different studies. Compared to the present results, the only non-contradictory 
conclusion is that EP3 mRNA increases during the secretory phase, most probably during mid-secretory phase 
[25,97,122,123].  
Endometrial diseases are all sex hormones related to some extent. Considering PGE2 and its related 
enzymes and receptors fluctuate with the menstrual cycle and play a role in the pathogenesis of endometrial 
diseases, it is proposed that PGE2 and sex hormones are also closely related in the endometrium under 
pathologic conditions (Fig. 3). In ESCs, PGE2 is demonstrated to be a potent stimulator of aromatase, a key 
enzyme catalyzing the final step of estrogen biosynthesis from testosterone, and estrogen receptor (ER) β 
expression and thus amplifies E2 synthesis through multi-mechanisms [124,125]. Meanwhile, suppression of 
aromatase diminishes the PGE level in peritoneal fluid in surgery-induced endometriosis mouse model [126]. 
Taken together, a positive feedback loop of COX-2/PGE2 and estrogen in endometriosis is established [127]. 
Besides interactions between them, E2/ERβ and PGE2/PKA work in conjunction to promote endometriotic  cell 
proliferation by transcriptional and post-translational modulations of Ras-like, estrogen-regulated, growth 
inhibitor (RERG) [128]. A positive correlation between COX-2, ERα and aromatase is observed in type 1 EC 
[129], while another study reports COX-2 has a positive correlation with progesterone receptor (PR) A and PRB 
instead of with ER in EC [130]. On the other hand, the autocrine of estrogen is enhanced in EC cells in response 
to trigging COX-2/PGE2/aromatase signaling [131]. Progesterone could increase the oxytocin-induced PGE2 
formation of Ishikawa cells via inactivation of oxytocinase on the cell surface [132]. All the evidence supports 
the notion that COX-2/PGE2 and sex hormones in EC go hand in hand, although the exact expression patterns 
and regulatory mechanisms between them are not yet fully understood.   
4.6 Role of PGE2 in the pathology of the endometrium 
Despite a discrepancy in correlation between endometriosis and the risk of EC according to recent large cohort 
studies [94,95], these two diseases share at least two pathogenic mechanisms: dysregulation of hormone and 
chronic inflammation [96-99] and four biological features: inducing angiogenesis, sustaining proliferation and 
evading apoptosis, activating migration and invasion, and avoiding immune destruction [133-136]. Growing 
evidence shows that PGE2 is implicated in the regulation of all these processes (Fig. 3). 




Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are potent angiogenic 
factors in health and disease [137,138] and both elevated in pathologic endometrium including endometriosis 
and endometrial cancer [139-142].   
COX-2 silencing greatly interrupts the production of VEGF in either eutopic or ectopic ESC with 
endometriosis [143]. When mPGES-1 knockout mouse endometrial fragments were implanted to mPGES-1 
knockout mice, the expression of VEGF and microvessel density (MVD) of implanted tissue was significant 
suppressed compared with wild-type to wild-type implants [144]. Several studies identify that VEGF protein and 
MVD increases with COX-2 expression in endometrial carcinoma tissue [130,145]. PGE2 could induce the 
bFGF expression via EP2 by activating cAMP-dependent PKA pathway and its downstream c-Src pathway and 
thus transactivating the epidermal growth factor receptor (EGFR) and ERK pathway in EC cells [146]. This 
induction could be attenuated by etodolac, a COX-2 selective inhibitor, in a dose-dependent manner [147]. 
Moreover, following the same signaling pathway and transactivation of EGFR, PGE2-EP2 could also increase 
the secretion of VEGF in endometrial adenocarcinoma cells [148].   
4.6.2 Sustaining proliferation and evading apoptosis 
Highly expressed COX-2 and increased PGE2 level have been shown to promote the proliferation and inhibit the 
apoptosis in pathological endometrium [104,105]. These effects are mainly achieved by modifying series cell-
cycle regulator proteins, apoptosis-related proteins, and factors involved in oncogenesis. In EC tissue, elevated 
COX-2 protein levels are associated with increased Bcl-2 protein and survivin, two key components in inhibiting 
apoptosis, and decreased miR101, which could inhibit the growth of endometrial serous carcinoma cell line and 
is thus expressed rather low in endometrial serous adenocarcinomas [130,149,150]. Moreover, PGE2 could 
promote proliferation of endometrial cancer cells by enhancing small ubiquitin-like modifier 1 (SUMO-1) 
expression and inactivating tuberin, a tumor suppressor [104,151]. SUMO-1 is recently known to play a role in 
the growth of endometrial cancer cells by increasing SUMOylation of histone H4 and the effect of PGE2 on 
SUMO-1 is via EP4-mediated Wnt/β-catenin signaling pathway [104,152]. The blockade of PGE2/EP2 and 
PGE2/EP4 pathways are associated with anti-proliferation of human endometriotic epithelial cells and stromal 
cells by inducing cell cycle arrest through changing the expression of certain cyclins and cyclin-dependent 
kinases (CDKs) in a cell-specific manner [153]. Moreover, blocking the same pathways increases the interaction 
between antiapoptotic (Bcl-2 and Bcl-XL) and proapoptotic proteins (Bax and Bad), accelerates the release of 
cytochrome c, and ultimately activates intrinsic apoptosis in human endometriotic cells [154].  
4.6.3 Activating migration and invasion 
PGE2 mediated LPS-induced invasion and its level in culture media is positively correlated with migration and 
invasion in endometriotic cells [96,155]. Similarly, oxytocin and hepatocyte growth factor (HGF)-induced 
invasion and/or migration in EC cells are PGE2 and/or COX-2 dependent [156,157]. These actions might be 
mediated by enhancing matrix metalloproteinases (MMPs) secretion and activities, which is essential to 
extracellular matrix degradation and in turn, leads to tumor cell invasion and metastasis, via diverse EPs (EP1, 
EP2 or EP4) [104,156,158,159]. 




Abnormal amount and function of immune cells, including T lymphocytes, B lymphocytes, natural killer cells 
and Mφ, participate in endometrial disorders initiation and progression. Experiments in vitro with immune cells 
derived from women with endometriosis show that PGE2’s effect on immune suppression is achieved by 
inhibiting the growth of peripheral blood lymphocytes, the phagocytic ability of Mφ, the chemotaxis of 
peripheral blood polymorphonuclear leukocytes and natural killer (NK) cell activity [95,160,161]. Treatment 
with PGE2 ultimately leads to increased Escherichia coli colonies in vitro and endometriotic lesions in vivo 
[95,160]. In EC, it is reported that COX-2 restricts the filtration of cluster of differentiation (CD) 8+ T cells 
within cancer cell nest, and acts synergistically with tumor-derived mucins to escape from immune surveillance 
[162,163].  
Figure 3. The interaction between PGE2 and estrogen and the role of PGE2 in diseased endometrium. 
4.7 Aims of the studies 
4.7.1 Expression of EPs in healthy and diseased endometrium  
PGE2 is well described to be involved both in physiological functions, such as menstrual cycle and implantation, 
and in human endometrial pathologies [2]. Since PGE2 exerts its actions via its four receptors, it is necessary to 
understand the expression pattern of them in health and disease [2]. Although some expressions of them show a 
temporal-specific manner based on RNA levels across the menstrual cycle, the patterns vary wildly between 
different studies. Moreover, little research has been done into the expressions in endometriosis and EC. We 
hypothesized spatial-temporal expression of these receptors in health underlies the mechanisms that control the 
growth and function of the endometrium [2]. 
Therefore, we investigated the spatial-temporal expression of these receptors in healthy endometrium 
throughout the menstrual cycle at a protein level. Then in the pathological endometrium, we further investigated 
the receptors which changed their expression across the menstrual cycle. 




EP3 is reported to regulate the oncogenesis and progression of various tumors, such as human prostate, breast, 
liver, colon, oral cancer [11]. Although the uterus is one of the organs with most abundant EP3, only little is 
known about the contribution of EP3 in EC so far [11,104,164]. Since our preliminary experiment demonstrated 
EP3 peeks during the early secretory phase, we hypothesized that EP3 is correlated with sex hormones and 
works synergistically with sex hormones to promote the EC progression. 
Therefore, we investigated the EP3 expression in tissue samples of EC patients and its association with 
clinicopathologic characteristics and survival. We studied the mechanism of EP3’s effect on EC using human EC 
cells and established the rationale of PGE2’s tumor-promoting action in EC [11]. 
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Supplementary material 1 Representative microphotographs of positive (A) 
and negative controls (B) for EP1 in placenta tissue are shown. Scale bars 
equal 100 μm  
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In the absence of conception, human premenopausal endometrium undergoes a cyclic morphological change in 
response to fluctuating sex hormones and inflammatory mediators. PGE2 also changes according to the phases. 
Moreover, it is upregulated in both EC and endometriosis and well known to be involved in both physiological 
functions and human endometrial pathologies. Therefore, providing an insight into changes of its receptors in the 
endometrium under physiological and pathological conditions is vital to understand the mechanism of 
endometrial disorders. However, so far little is known about the expression patterns of them in health and disease. 
We analyzed the expression patterns of EPs in human nonpregnant endometrium throughout the 
menstrual cycle by immunohistochemistry (n = 42) and found EPs were located in the cytoplasm of both 
epithelial cells and stromal cells but not present in the nucleus. Next, we found the expression of both EP1 and 
EP3 demonstrated cyclical changes by comparing the intensity of EPs in three phases of menstrual cycle using a 
semiquantitative immunoreactive score (IRS). EP1 expression decreases during the early secretory phase (p = 
0.006), while EP3 expression behaves in the opposite way (p < 0.05). We thus focused our further analysis on 
these two receptor subtypes. 
The expressions of EP1 were compared among healthy endometrium, ovarian endometriosis, and EC. 
There were significant differences among these tissues in both epithelium (p = 0.001) and stroma (p < 0.001). 
EP1 staining in the epithelium was increased in endometriotic tissue compared to the healthy endometrium (p = 
0.042) and tumor tissue (p < 0.001), while in the stroma, the staining in the tumor was lower than that in both 
normal tissue (p < 0.001) and endometriosis (p < 0.001). However, no significant differences in EP1 intensity 
were detected among four endometriosis stages and among subtypes of histology, stage, grade, metastasis, and 
recurrence in EC. Consistently, EP1 was also correlated with neither progression-free survival nor overall 
survival of patients with cancer. Besides that, we made an interesting discovery that EP1 staining varied by PRB 
status. The staining in the PRB-positive tumor was stronger compared to the PRB-negative tumor.  
EP3 has been revealed to regulate tumor cell proliferation, migration, and invasion in numerous cancers. 
However, the role of EP3 as a prognostic biomarker in EC remains unclear. Therefore, the primary aim of the 
further study was to analyze the prognostic significance of EP3 expression in EC. EP3 expression of 140 
endometrial carcinoma patients was determined by immunohistochemistry. RL95-2 endometrial cancer cell line 
was chosen from four endometrial cancer cell lines (RL95-2, Ishikawa, HEC-1-A, and HEC-1-B) according to 
EP3 expression level. Treated with PGE2 and EP3 antagonist, RL95-2 cells were investigated by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 5-bromo-2′-deoxyuridine (BrdU) and wound 
healing assay for functional assessment of EP3. EP3 staining was statistically associated with tumor grade in 
both whole cohort (p = 0.01) and the subgroup of endometrioid carcinoma (p = 0.01). Patients with high EP3 
expression in their respective tumors had impaired progression-free survival as well as overall survival in both 
cohorts above. EP3 expression in the overall cohort was identified as an independent prognostic marker for 
progression-free survival (HR 1.014, 95%CI 1.003-1.024, p = 0.01) when adjusted for age, stage, grade, and 
recurrence. Besides, a significant negative correlation between EP3 and ERβ (correlation coefficient r = -0.225; 




activity of Ras and led to attenuated proliferation and migration of RL95-2 cells, while the treatment had no 
effect on E2 biosynthesis. 
In conclusion, EP1 is upregulated during the proliferative phase, which is in accordance with its effect 
on inducing angiogenesis and promoting Th1 differentiation. Although the exact mechanism for EP1’s action in 
endometriosis is unknown, we speculate it might be related to its role in proinflammation and production of 
estrogen according to previous studies. Furthermore, the expression of EP1 is positively correlated with PRB, 
which is decreased sharply in EC and inhibits invasion as well as recurrence of EC, suggesting a protective role 
of EP1 in EC. Regarding EP3, we confirm that its expression in glandular epithelial cells is associated with 
tumor grade and predicts poor prognosis of EC. EP3 plays a crucial role in EC progression by regulating 
proliferation and migration of tumor cells and modulating ERβ and the activity of Ras. In the context of limited 
systemic treatment options for endometrial cancer, this explorative analysis identifies EP3 as a potential target 
for diagnostic workup and therapy. 
Taken together these studies, PGE2 not only participates in the physiology of the female reproductive 
system but also is involved in the benign and malignant endometrial diseases via its specific receptors. Thus, 
further studies are needed to connect the obtained knowledge of the molecular mechanisms of these receptors 






Als Reaktion auf fluktuierende Sexualhormone und Entzündungsmediatoren unterliegt menschliches 
prämenopausales Endometrium ausserhalb einer Schwangerschaft zyklischen morphologischen Veränderungen. 
Auch die Expression von PGE2, das in physiologische sowie pathologische Prozesse des Endometriums 
involviert ist, unterliegt zyklischen Schwankungen. Zudem wird die Expression sowohl bei 
Endometriumskarzinomen, als auch in bei Endometriose hochreguliert. Daher scheint eine Untersuchung der 
Veränderungen der endometrialen Prostaglandinrezeptoren essentiell, um die Mechanismen endometrialer 
Störungen zu verstehen. Bislang jedoch ist nur wenig über das Expressionsverhalten dieser Rezeptoren unter 
physiologischen Bedingungen und bei Erkrankungen des Endometriums bekannt.  
In der vorliegenden Arbeit haben wir retrospektiv die Expressionsmuster und -intensitäten von EPs in 
humanem endometrialem Gewebe (n=42) während des Menstruationszyklusses mittels Immunhistochemie 
untersucht. Die EP-Expression konnte im Zytoplasma sowohl von epithelialen Zellen, also auch von 
Stromazellen nachgewiesen warden, nicht aber in den Nuclei dieser Zellen. EP1 und EP3 zeigten zyklische 
Veränderungen in der Intensität ihrer Expression. Während sich die EP1-Expression in der frühen 
Sekretionsphase verminderte (p=0.006), verhielt sich die EP3-Expression gegenteilig (p<0.05).  
In der Folge wurden die Unterschiede der EP1- und EP3- Expression bei gesundem endometrialem 
Gewebe, ovarieller Endometriose und Endometriumskarzinomen verglichen. Signifikante Unterschiede zeigten 
sich im endometrialen Epithel und Stroma: Bei Endometriose war die epitheliale EP1-Expression im Vergleich 
zu gesundem Gewebe (p=0.042) und zu Tumorgewebe erhöht (p<0.001). Die Expression im Stroma zeigte sich 
bei Tumorgewebe vermindert, verglichen mit gesundem Gewebe (p<0.001) und Gewebe von Endometriose-
Patientinnen (p<0.001). Die EP1-Expression bei Endometriumskarzinomen unterschied sich nicht significant 
hinsichtlich Tumorhistologie, Stadium, Grad, Metastasierung und Wiederauftreten des Tumors. EP1 korreliert 
weder mit progressionsfreiem Überleben noch mit dem Gesamtüberleben der Patienten. Allerdings wiesen die 
PR-B-positiven Tumore eine stärkere EP1-Anfärbung auf als PR-B-negative.  
Der Rezeptor EP3 reguliert die Proliferation, Migration und Invasion von Tumorzellen in einer Vielzahl 
von unterschiedlichen Karzinomen. Die mögliche Rolle von EP3 als prognostischer Biomarker im 
Endometriumskarzinom ist jedoch bislang unklar. Daher untersuchten wir auch die prognostische Signifikanz 
der EP3-Expression in Endometriumskarzinomen von 140 Patienten. Hierzu wurde die 
Endometriumskarzinomzellinie RL95-2 anhand ihres ähnlichen EP3-Exprssionslevels aus vier relevanten 
Ziellinien ausgewählt (RL95-2, Ishikawa, HEC-1-A, und HEC-1-B). Versetzt mit PGE2- und EP3-Antagonisten 
wurden die RL95-2-Zellen mit Hilfe von MTT-, BrdU- und „wound healing-“Assays analysiert, um die 
Funktionalität von EP3 zu beurteilen. Abhängig vom Tumorstadium konnten signifikante Unterschiede in der 
EP3-Anfärbung sowohl in der gesamten Kohorte (p = 0,01), als auch in der Subgruppe mit 
Endometriumskarzinom (p = 0,01) nachgewiesen werden: Patienten mit hoher EP3-Expression in ihren 
jeweiligen Tumoren zeigten ein schlechteres progressionsfreies Überleben sowie Gesamtüberleben. In der 
Gesamtkohorte wurde die EP3-Expression nach Adjustierung von Alter, Stadium, Grad und Rezidiv als 
unabhängiger Prognosefaktor für progressionsfreies Überleben identifiziert (HR 1.014, 95%CI 1.003-1.024, p = 




r = -0,225; p = 0,011) gefunden. Eine Behandlung mit EP3-Antagonisten induzierte eine Hochregulierung von 
ER-β, eine Verminderung der Ras-Aktivität und führte zur Abschwächung der Proliferation und Migration von 
RL95-2-Zellen. Kein Effekt konnte auf die Biosynthese von auf die nachgewiesen werden. 
Somit scheint EP3 eine entscheidende Rolle in der Progression des Endometriumskarzinoms zu spielen. 
Im Kontext von limitierten systematischen Therapieoptionen für das Endometriumskarzinom, stellt diese 
descriptive Analyse von EP3 als potentiellem therapeutischem Target einen vielversprechenden translationalen 
Ansatz für diagnostische und therapeutische Entwicklungen dar.  
Zusammenfassend für beide Teile der Arbeit ist festzustellen, dass Prostaglandine (PGE2) nicht nur die 
physiologischen Prozesse der Endometriumsdifferenzierung beeinflussen sondern auch benigne und maligne 
Transformationen des Endometriums über spezifische Rezeptoren steuern. Es sind noch weiterführende Studien 
notwendig, um gefundene Modulatoren dieser Rezeptoren im Sinne translationaler Prozesse in den klinischen 
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